Vaccination treatment and knowledge in patients with bronchiectasis

  • Research type

    Research Study

  • Full title

    Understanding vaccine uptake and rates of invasive pneumococcal disease in Adult Bronchiectasis -an at risk population

  • IRAS ID

    137729

  • Contact name

    Anthony De Soyza

  • Contact email

    anthony.desoyza@nuth.nhs.uk

  • Sponsor organisation

    The Newcastle upon Tyne Hospitals NHS Foundation Trust

  • Research summary

    Bronchiectasis is a chronic airway infection syndrome with an attendant risk of pneumonia. The pneumonia risk is poorly defined but in our clinic of 400 patients 1% risk per year has been noted. Bronchiectasis is a rarer disease than asthma or COPD with unclear prevalence data. Local registry data has however demonstrated over 1000 patients in North East England; hence this condition is 3 times more common than cystic fibrosis. Bronchiectasis is recognised as a chronic respiratory disease and should therefore be included in primary care vaccination schedules. \nIn line with national Bronchiectasis and national vaccination guidelines it is standard practice at this centre to request details of pneumococcal vaccination from primary care and ask vaccination to be considered if this has not been done.\nThe study designed to develop a representation of patient vaccination, education and information given at time of vaccination. We also aim to develop an understanding of defined pneumonia rates and vaccination practice in the North East of England.\n

  • REC name

    West Midlands - South Birmingham Research Ethics Committee

  • REC reference

    13/WM/0484

  • Date of REC Opinion

    20 Nov 2013

  • REC opinion

    Favourable Opinion